50POST — Every State. Every Story. My 50POST ↗
LAWS & TAXES / BRIEFING

Agency notice: CDC seeks comment on proposed West Nile antibody profile

Federal · applicability depends on the document

50POST news graphic: Agency notice: CDC seeks comment on proposed West Nile antibody profile
50POST news graphic · story-specific information

The CDC has opened a docket for comments and suggestions on the proposed profile.

The profile aims to set minimal and optimal attributes for a West Nile virus monoclonal antibody product for pre- or post-exposure prevention in patients at higher risk of severe disease.

Based on the linked record from Federal Register ↗. Our reporting and verification standards.

A federal document is not a determination of how a law applies to you. A published rule may have a separate effective date. Consult the official record for its terms.
Source, dates and supporting record
Source published
Nov 16, 2026
Last checked
Nov 18, 2026, 4:55 PM EST
Record status
Agency notice
Comment deadline
Jan 15, 2027

Read the original record ↗

Supporting excerpts

The Centers for Disease Control and Prevention (CDC) in the Department of Health and Human Services (HHS) announces the opening of a docket to obtain comment on the proposed Target Product Profile for Monoclonal Antibodies for West Nile Virus Disease Prevention.
This Request for Information (RFI) invites comments and suggestions on the proposed target product profile.
The objective of the target product profile is to describe key minimal and optimal attributes for a West Nile virus monoclonal antibody product that can be provided to patients at higher risk for severe West Nile virus disease as pre- or post- exposure prophylaxis.

Original source text

The Centers for Disease Control and Prevention (CDC) in the Department of Health and Human Services (HHS) announces the opening of a docket to obtain comment on the proposed Target Product Profile for Monoclonal Antibodies for West Nile Virus Disease Prevention. This Request for Information (RFI) invites comments and suggestions on the proposed target product profile. The objective of the target product profile is to describe key minimal and optimal attributes for a West Nile virus monoclonal antibody product that can be provided to patients at higher risk for severe West Nile virus disease as pre- or post- exposure prophylaxis. This input is a valuable component in developing a useful target product profile.

Source wording and its time zone may differ. Date-only dates are preserved. Timestamps here use Eastern Time. Evidence version: ac7c0bc9979a14036d10ebdeb4431187da9a841bd96c461d4b7ba1a4350ac57c

Source guidance

Consult the linked document and official PDF. Publication does not by itself establish that a rule is currently in force.

Original guidance from the issuing source. For current warnings and instructions, consult that source directly. This site is not an emergency notification service.

Something doesn’t look right?

Tell the editor what needs checking. Please avoid personal or sensitive details.

Sign in if needed to submit a report